cd-265

MGCD-265 analog (Glesatinib) 是一种口服生物可利用的多靶点酪氨酸激酶抑制剂，具有抗肿瘤活性，对 c-Met 和 VEGFR2 的 IC50 分别为 29 nM 和 10 nM。

Glesatinib is an orally active and potent dual inhibitor of MET SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.

Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.